TG Therapeutics shareholders reject advisory say-on-pay and annual frequency vote

TG THERAPEUTICS, INC.

Proposal 4 (advisory vote on executive compensation) defeated: 25.8M for, 61.2M against.
Proposal 5 (advisory vote on frequency): 66.9M voted for annual, but board will retain triennial frequency.
Director Yann Echelard and Daniel Hume each received only ~31.5% support, Sagar Lonial got 26.4%.
Shareholders approved 2022 Incentive Plan (53.9M for, 33.3M against) and ratified KPMG (114.0M for).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.